Trials / Sponsors / RayzeBio, Inc.
RayzeBio, Inc.
Industry · 5 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease | Phase 1 | 2025-12-03 |
| Recruiting | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | 2025-09-05 |
| Active Not Recruiting | Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer | Phase 1 / Phase 2 | 2024-07-19 |
| Active Not Recruiting | Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC SCLC,Extensive Stage | Phase 1 | 2022-10-10 |
| Recruiting | Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Fo GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease | Phase 3 | 2022-03-24 |